PolyPid Ltd. POLY 深 沪
等待开盘 04-01 09:30:00 美东时间
39.82
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 39.82
- 总市值 17.52亿
- 52周最高 40.82
- 市盈率 静 97.67
- 换手率 0.00%
- 52周最低 22.69
- 委 比 0.00%
- 总股本 4399.39万
- 历史最高 81.23
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.60
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
PolyPid Ltd. has initiated the submission of its New Drug Application (NDA) to the FDA for D-PLEX₁₀₀, aimed at preventing surgical site infections (SSIs) in colorectal surgery patients. The submission, under the FDA’s Fast Track designation, includes the Chemistry, Manufacturing and Controls (CMC) and nonclinical sections, with the clinical section expected in the second quarter of 2026. D-PLEX₁₀₀, which uses PolyPid’s Kynatrix technology, provid...
03-31 12:30
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
PolyPid Ltd. announced that the FDA has granted a $4.3 million small business waiver for its New Drug Application (NDA) for D-PLEX₁₀₀, aimed at preventing surgical site infections in abdominal colorectal surgeries. This waiver supports the company's commercialization efforts and enables it to focus on submitting the first sections of its rolling NDA by the end of this month. D-PLEX₁₀₀ demonstrated a 60% relative risk reduction in infections in th...
03-17 12:30
PolyPid Appoints Brooke Story As Board Chairman, Effective Dec. 11
PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors,
2025-12-16 21:33
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
PolyPid Ltd. announced the appointment of Brooke Story as Chairman of its Board of Directors. With over 25 years of leadership experience in the MedTech industry, Story will enhance the company’s strategic, commercial, and transaction capabilities. Her expertise in surgical solutions and infection prevention will support PolyPid in advancing its lead product, D-PLEX₁₀₀, which is expected to submit its New Drug Application in early 2026. Story’s l...
2025-12-16 13:30
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission
PolyPid Ltd. has received FDA support for rolling NDA submission of D-PLEX100, its lead product for preventing surgical site infections in colorectal surgeries. The FDA agreed the company's existing clinical data, including Phase 3 results, is adequate for submission. PolyPid plans to submit the first sections in early 2026, with the Breakthrough Therapy designation further validating its regulatory strategy.
2025-12-03 13:30
PolyPid Advances D-PLEX₁₀₀ Towards FDA Submission and Commercial Readiness
PolyPid ( ($PYPD) ) has shared an announcement. PolyPid Ltd. announced its thir...
2025-11-12 20:56
PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"
PolyPid's D-PLEX₁₀₀, designed to prevent surgical site infections (SSIs) via extended, localized antibiotic delivery, has been named "Therapeutics Solution of the Year" by BioTech Breakthrough. With Phase 3 results showing a 58% relative risk reduction in SSIs, the product, leveraging PolyPid's PLEX technology, delivers doxycycline for 30 days directly at the surgical site. Widespread SSIs remain a critical issue, causing extended hospital stays ...
2025-11-06 13:30
金色早报丨Polymarket将于11月底前重返美国 代币化平台Securitize将通过SPAC上市
预测市场平台Polymarket即将向美国用户重新开放，并推出POLY代币和空投；Securitize将通过SPAC合并上市。加密货币市场整体跌幅明显。美国加密PAC筹资超能源行业，挪威加密申报激增。香港金管局计划将数字港元推广至个人用户。以太坊Fusaka硬分叉预计12月上线，提升可扩展性和安全性。 Mellon Prefix = synonym
2025-10-28 23:47
Inside The Speculation: Why Traders Think Polymarket's POLY Airdrop Could Be The Next Billion-Dollar Crypto Windfall
Can truth be tokenized?
2025-10-24 20:55
